ReviewClinical and experimental gastroenterology2019
Beneficial effects of
Review in Clinical and experimental gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- The effectiveness of treatment with probiotics in preventing necrotizing enterocolitis and related mortality: results from an umbrella meta-analysis on meta-analyses of randomized controlled trials.BMC gastroenterology · 2025Pooled it
- Biofilm overproduction enhances gastrointestinal stress tolerance and intestinal fitness inGut microbes · 2026Article
- Non-Conventional Yeasts with Probiotic Potential: Diversity, Functional Role, Sustainable Bioprocessing and Local Relevance.Microorganisms · 2026Review
- The Programmable Microbiome: Integrative AI and Multi-Omics Frameworks for Precision T2DM Management.Biology · 2026Review
- Managing Gut Dysbiosis: Clinical Evidence and Perspectives onMicroorganisms · 2026Review
- Functional assessment of coffee cherry-derived non-conventional yeasts identifies promising candidates for probiotic and postbiotic applications.Frontiers in microbiology · 2026Article
- Application ofFoods (Basel, Switzerland) · 2025Review
- Alfalfa Polysaccharide Alleviates Colitis by Regulating Intestinal Microbiota and the Intestinal Barrier Against the TLR4/MyD88/NF-κB Pathway.Nutrients · 2025Article
- Oral Treatment with Saccharomyces cerevisiae CNCM I-3856 Mitigates the Inflammatory Response Experimentally Induced by Salmonella enterica subsp. enterica Serovar Typhimurium in Mice.Probiotics and antimicrobial proteins · 2025Article
- Collagen Peptides andFood science & nutrition · 2025Article
- Mechanism of Action and Beneficial Effects of Probiotics in Amateur and Professional Athletes.Food science & nutrition · 2025Review
- Gut-lung axis in allergic asthma: microbiota-driven immune dysregulation and therapeutic strategies.Frontiers in pharmacology · 2025Review
- Probiotics and the intestinal tight junction barrier function.Frontiers in cell and developmental biology · 2025Review
- Review
- The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story.Microorganisms · 2024Review
- Research Progress for Probiotics Regulating Intestinal Flora to Improve Functional Dyspepsia: A Review.Foods (Basel, Switzerland) · 2024Review
- The supplementation of female dogs with live yeastFrontiers in nutrition · 2024Article
- Evaluation of the impact of polypeptide-p on diabetic rats upon its cloning, expression, and secretion in Saccharomyces boulardii.Archives of microbiology · 2023Article
- A metabolite from commensal Candida albicans enhances the bactericidal activity of macrophages and protects against sepsis.Cellular & molecular immunology · 2023Article
- The Gut Microbiome and Ferroptosis in MAFLD.Journal of clinical and translational hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal barrier defects lead to "leaky gut syndrome", defined as an increase in intestinal permeability that allows the passage of luminal content into intestinal tissue and the bloodstream. Such a compromised intestinal barrier is the main factor underlying the pathogenesis of inflammatory bowel disease, but also commonly occurs in various systemic diseases such as viral infections and metabolic syndrome. The non-pathogenic yeast
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.